ClinicalTrials.gg
CompletedNCT00664521August IIIUpdated Dec 30, 2016Results posted

Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)

A Phase 2 interventional study of Rituximab and Atacicept in Rheumatoid Arthritis, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 8 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-30.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 357 studies in Arthritis, Rheumatoid with a site in France — 42 open to participants now, 62 under way, 6 of them phase 3. Arthritis, Rheumatoid · France.

Enrollment
197th of 222
27 · median 167
Started
2008
with 17 others
Phase 2
33 of 357
4 open now
Registered
44th of 357
by date

Among the 357 studies in Arthritis, Rheumatoid with a site in France, this one is the 197th largest by enrollment of the 222 interventional ones that give a count, is one of 18 that started in 2008, is one of 33 in phase 2, and was the 44th registered.

Arthritis, Rheumatoid

3,338 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

42 of the 357 studies in Arthritis, Rheumatoid with a site in France are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 357 studies in Arthritis, Rheumatoid with a site in France, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the safety and tolerability of combined treatment with atacicept and rituximab in subjects with active rheumatoid arthritis (RA) receiving re-treatment with rituximab.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects
  • Greater than and equal to (>=) 18 years of age at the time of
  • Who have rheumatoid arthritis satisfying American College of Rheumatology (ACR) criteria with a disease history of at least 12 months
  • Subjects must have active disease defined by DAS28 >3.2
  • Subjects must have received previous treatment with rituximab and must be candidates for re-treatment with rituximab
  • Female subjects of must be willing to avoid pregnancy by using an adequate method of for 4 weeks before study day 1 (SD1), during the treatment period and for 12 months after the last dose of rituximab, and must have a negative urine pregnancy test at the screening visit and SD1
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Current neurological disease excluding migraine
  • Inflammatory joint disease other than rheumatoid arthritis
  • Any to rituximab as per national label
  • Use of disease-modifying anti-rheumatic drugs (DMARDs; including methotrexate) for less than 3 months or change in dosing regimen within 28 days before SD1, or methotrexate dose regimen >25 mg/week
  • Participation in any interventional clinical trial within 1 month before SD1 (or within 5 half-lives of the investigated compound before SD1, whichever is longer)
  • Prednisone dose regimen >10 mg/day (or equivalent), or change in dosing regimen within 28 days before SD1
  • Active or latent tuberculosis within the year before screening or major infection requiring hospitalization or intravenous anti-infectives within 28 days before SD1
  • Serum Immunoglobulin G (IgG) below 6 gram per liter (g/L)
  • Known to atacicept or to any of the components of the formulated atacicpet
  • Known hypersensitivity to rituximab, to any of the components of the formulated rituximab or to murine proteins
  • Breastfeeding or pregnancy
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Rituximab Plus Atacicept

    Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3, followed by atacicept 150 mg subcutaneously once a week from Week 7 to 32.

    Biological: Rituximab · Drug: Atacicept

  • Placebo comparator
    Rituximab Plus Placebo

    Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3, followed by placebo matched to atacicept subcutaneously once a week from Week 7 to 32.

    Biological: Rituximab · Drug: Placebo matched to atacicept

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.

    Time frame: Baseline up to Week 64

  2. Percentage of Participants With Immunoglobulin G (IgG) Level Less Than 3 Gram Per Liter (g/L)

    Time frame: Week 64

  3. Percent Change From Baseline in Vital Signs and Routine Safety Lab Parameters at Week 32

    Vital signs assessed included blood pressure (systolic and diastolic), pulse and body temperature. Routine safety lab parameters evaluated included red blood cell (RBC), hemoglobin, hematocrit, platelets, mean cellular hemoglobin (MCH), MCH concentration, MCH volume, white blood cell (WBC), lymphocytes, monocytes, eosinophils, basophils, neutrophils, gamma glutamyl transferase (GGT), alanine aminotransferase (ALT), albumin, alkaline phosphatase (AP), aspartate aminotransferase (AST), bilirubin, calcium, creatinine, glucose, potassium, total protein, sodium, uric acid, and blood urea nitrogen. Percent change from baseline was calculated as (\[Week 32 value minus baseline value\] multiplied by 100) divided by baseline value.

    Time frame: Baseline, Week 32

  4. Percent Change From Baseline in Anti-tetanus and Anti-diphteria Immunization Titer at Week 32

    Percent change from baseline was calculated as (\[Week 32 value minus baseline value\] multiplied by 100) divided by baseline value.

    Time frame: Baseline, Week 32

  5. Percent Change From Baseline in Anti-pneumococcus Titer at Week 32

    Percent change from baseline was calculated as (\[Week 32 value minus baseline value\] multiplied by 100) divided by baseline value.

    Time frame: Baseline, Week 32

Secondary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP), ACR50-CRP and ACR70-CRP at Week 32

    ACR20-CRP response: greater than or equal to (\>=) 20 percent (%) improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=20% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP). ACR50-CRP and ACR70-CRP response are defined as \>=50% and \>=70% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) respectively together with \>=50% and \>=70% improvement in at least 3 of the following respectively: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) CRP.

    Time frame: Week 32

  2. Change From Baseline in Disease Activity Score in 28 Joints (DAS28) Based on CRP (DAS28-CRP) at Week 32

    DAS28-CRP incorporates non-graded joint counts for tenderness and swelling based on a total of 28 joints, CRP as a marker of inflammation, and a general health assessment using a 100 mm visual analog scale (the participant's global assessment of disease activity). DAS28 score ranges between 0 and 10 representing current disease activity. A value above 5.1 represents high disease activity, a value below 3.2 represents low disease activity, and a value below 2.6 represents remission.

    Time frame: Baseline, Week 32

  3. Median Percentage Change From Baseline in Levels of Total, Mature and Memory B Cells

    Flow cytometric analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of total, mature and memory B cell levels.

    Time frame: Baseline, Week 3, 7, 12, 16, 26 and 32

07

Results

Posted Dec 30, 2016

Participant flow

Participant flow — Overall Study
MilestoneRituximab Plus AtaciceptRituximab Plus Placebo
Started189
Completed128
Not completed61
Withdrew: Adverse event41
Withdrew: Lost to follow-up10
Withdrew: Other10

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.

Time frame:
Baseline up to Week 64
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsRituximab Plus AtaciceptRituximab Plus Placebo
AEs179
SAEs62
PrimaryPercentage of Participants With Immunoglobulin G (IgG) Level Less Than 3 Gram Per Liter (g/L)
Time frame:
Week 64
Reported as:
Number · percentage of participants
Percentage of Participants With Immunoglobulin G (IgG) Level Less Than 3 Gram Per Liter (g/L)
percentage of participantsRituximab Plus AtaciceptRituximab Plus Placebo
Percentage of Participants With Immunoglobulin G (IgG) Level Less Than 3 Gram Per Liter (g/L)00
PrimaryPercent Change From Baseline in Vital Signs and Routine Safety Lab Parameters at Week 32

Vital signs assessed included blood pressure (systolic and diastolic), pulse and body temperature. Routine safety lab parameters evaluated included red blood cell (RBC), hemoglobin, hematocrit, platelets, mean cellular hemoglobin (MCH), MCH concentration, MCH volume, white blood cell (WBC), lymphocytes, monocytes, eosinophils, basophils, neutrophils, gamma glutamyl transferase (GGT), alanine aminotransferase (ALT), albumin, alkaline phosphatase (AP), aspartate aminotransferase (AST), bilirubin, calcium, creatinine, glucose, potassium, total protein, sodium, uric acid, and blood urea nitrogen. Percent change from baseline was calculated as (\[Week 32 value minus baseline value\] multiplied by 100) divided by baseline value.

Time frame:
Baseline, Week 32
Reported as:
Mean · Percent change
Percent Change From Baseline in Vital Signs and Routine Safety Lab Parameters at Week 32
Percent changeRituximab Plus AtaciceptRituximab Plus Placebo
Systolic Blood Pressure (n = 12, 9)3.74 ± 11.76-6.29 ± 13.80
Diastolic Blood Pressure (n = 12, 9)1.09 ± 11.194.89 ± 10.09
Pulse (n = 12, 9)10.21 ± 19.93-8.54 ± 11.98
Temperature (n = 10, 8)0.23 ± 1.05-0.44 ± 0.86
RBC (n = 12, 9)3.10 ± 5.304.94 ± 7.18
Hemoglobin (n = 12, 9)2.55 ± 5.324.93 ± 6.18
Hematocrit (n = 12, 9)2.39 ± 6.306.05 ± 6.15
Platelets (n = 12, 9)-6.80 ± 21.21-2.49 ± 37.62
MCH (n = 12, 9)-0.32 ± 5.030.22 ± 3.21
MCH Concentration (n = 12, 9)-0.18 ± 2.01-1.41 ± 1.47
MCH Volume (n = 12, 9)-0.06 ± 4.981.39 ± 2.73
WBC(n = 12, 9)-14.59 ± 36.85-9.70 ± 19.15
Lymphocytes (n = 12, 9)0.27 ± 30.11-5.68 ± 23.00
Monocytes (n = 12, 9)5.01 ± 70.441.88 ± 38.51
Eosinophils (n = 12, 9)34.11 ± 103.78-7.51 ± 34.58
Basophils (n = 12, 9)-20.45 ± 58.6132.41 ± 117.44
Neutrophils (n = 12, 9)-11.29 ± 57.75-13.09 ± 24.01
GGT (n = 12, 9)-3.21 ± 30.3710.17 ± 53.33
ALT (n = 12, 9)17.52 ± 27.8917.79 ± 53.23
Albumin (n = 12, 9)6.22 ± 6.346.43 ± 8.10
AP (n = 12, 9)4.85 ± 18.86-5.41 ± 16.48
AST (n = 12, 9)14.53 ± 30.876.73 ± 36.47
Bilirubin Total (n = 12, 9)15.09 ± 42.784.76 ± 14.29
Calcium (n = 12, 9)-1.07 ± 5.042.61 ± 4.72
Creatinine (n = 12, 9)-3.29 ± 10.305.89 ± 5.26
Glucose (n = 12, 9)3.71 ± 18.557.99 ± 22.71
Potassium (n = 12, 9)-0.93 ± 6.344.67 ± 9.37
Total Protein (n = 12, 9)-2.83 ± 7.084.17 ± 6.57
Sodium (n = 12, 9)1.21 ± 1.460.25 ± 1.63
Uric Acid (n = 12, 9)-2.95 ± 12.60-0.72 ± 6.10
Blood Urea Nitrogen (n = 12, 9)1.63 ± 27.04-7.42 ± 26.02
PrimaryPercent Change From Baseline in Anti-tetanus and Anti-diphteria Immunization Titer at Week 32

Percent change from baseline was calculated as (\[Week 32 value minus baseline value\] multiplied by 100) divided by baseline value.

Time frame:
Baseline, Week 32
Reported as:
Median · percent change
Percent Change From Baseline in Anti-tetanus and Anti-diphteria Immunization Titer at Week 32
percent changeRituximab Plus AtaciceptRituximab Plus Placebo
Anti-tetanus Immunization Titer-17.98 (-34.29 to 0.00)0.00 (-7.67 to 23.68)
Anti-diphtheria Immunization Titer-33.68 (-50.00 to 0.00)8.41 (0.39 to 33.93)
PrimaryPercent Change From Baseline in Anti-pneumococcus Titer at Week 32

Percent change from baseline was calculated as (\[Week 32 value minus baseline value\] multiplied by 100) divided by baseline value.

Time frame:
Baseline, Week 32
Reported as:
Median · percent change
Percent Change From Baseline in Anti-pneumococcus Titer at Week 32
percent changeRituximab Plus AtaciceptRituximab Plus Placebo
Percent Change From Baseline in Anti-pneumococcus Titer at Week 32-18.49 (-35.18 to 0.00)0.00 (0.00 to 0.00)
SecondaryPercentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP), ACR50-CRP and ACR70-CRP at Week 32

ACR20-CRP response: greater than or equal to (\>=) 20 percent (%) improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=20% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP). ACR50-CRP and ACR70-CRP response are defined as \>=50% and \>=70% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) respectively together with \>=50% and \>=70% improvement in at least 3 of the following respectively: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) CRP.

Time frame:
Week 32
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP), ACR50-CRP and ACR70-CRP at Week 32
percentage of participantsRituximab Plus AtaciceptRituximab Plus Placebo
ACR20-CRP33.322.2
ACR50-CRP11.111.1
ACR70-CRP5.60
SecondaryChange From Baseline in Disease Activity Score in 28 Joints (DAS28) Based on CRP (DAS28-CRP) at Week 32

DAS28-CRP incorporates non-graded joint counts for tenderness and swelling based on a total of 28 joints, CRP as a marker of inflammation, and a general health assessment using a 100 mm visual analog scale (the participant's global assessment of disease activity). DAS28 score ranges between 0 and 10 representing current disease activity. A value above 5.1 represents high disease activity, a value below 3.2 represents low disease activity, and a value below 2.6 represents remission.

Time frame:
Baseline, Week 32
Reported as:
Mean · Units on a scale
Change From Baseline in Disease Activity Score in 28 Joints (DAS28) Based on CRP (DAS28-CRP) at Week 32
Units on a scaleRituximab Plus AtaciceptRituximab Plus Placebo
Baseline (n = 18, 9)5.50 ± 0.995.81 ± 1.04
Change at Week 32 (n = 12, 9)3.85 ± 0.984.25 ± 1.10
SecondaryMedian Percentage Change From Baseline in Levels of Total, Mature and Memory B Cells

Flow cytometric analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of total, mature and memory B cell levels.

Time frame:
Baseline, Week 3, 7, 12, 16, 26 and 32
Reported as:
Median · percent change
Median Percentage Change From Baseline in Levels of Total, Mature and Memory B Cells
percent changeRituximab Plus AtaciceptRituximab Plus Placebo
Total B cells (Week 3: n=18, 9)-100.00 (-100.00 to -100.00)-100.00 (-100.00 to -100.00)
Total B cells (Week 7: n=17, 8)-100.00 (-100.00 to -100.00)-99.69 (-100.00 to -96.96)
Total B cells (Week 12: n=16, 9)-100.00 (-100.00 to -100.00)-100.00 (-100.00 to -100.00)
Total B cells (Week 16: n=15, 9)-100.00 (-100.00 to -100.00)-100.00 (-100.00 to -100.00)
Total B cells (Week 26: n=12, 9)-100.00 (-100.00 to -93.06)-94.74 (-100.00 to -71.43)
Total B cells (Week 32: n=12, 9)-86.99 (-98.26 to -50.00)-68.11 (-100.00 to -35.00)
Mature B Cells (Week 3: n=18, 9)-100.00 (-100.00 to -100.00)-100.00 (-100.00 to -100.00)
Mature B Cells (Week 7: n=17, 8)-100.00 (-100.00 to -100.00)-100.00 (-100.00 to -100.00)
Mature B Cells (Week 12: n=16, 9)-100.00 (-100.00 to -47.78)-100.00 (-100.00 to -100.00)
Mature B Cells (Week 16: n=15, 9)-100.00 (-100.00 to -100.00)-100.00 (-100.00 to -100.00)
Mature B Cells (Week 26: n=12, 9)-100.00 (-100.00 to -100.00)-100.00 (-100.00 to -85.11)
Mature B Cells (Week 32: n=12, 9)-99.35 (-100.00 to -22.73)-84.47 (-100.00 to -48.94)
Memory B cells (Week 3: n=18, 9)-100.00 (-100.00 to -100.00)-100.00 (-100.00 to -100.00)
Memory B cells (Week 7: n=17, 8)-100.00 (-100.00 to -66.67)-100.00 (-100.00 to -100.00)
Memory B cells (Week 12: n=16, 9)-100.00 (-100.00 to -68.33)-100.00 (-100.00 to -100.00)
Memory B cells (Week 16: n=15, 9)-100.00 (-100.00 to -100.00)-100.00 (-100.00 to -66.67)
Memory B cells (Week 26: n=12, 9)-100.00 (-100.00 to -82.50)-88.89 (-100.00 to -25.00)
Memory B cells (Week 32: n=12, 9)-83.33 (-100.00 to -25.00)-50.00 (-100.00 to -44.44)

Adverse events

Collected over Baseline up to Week 64. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab Plus Atacicept—6/18 (33.3%)17/18 (94.4%)
Rituximab Plus Placebo—2/9 (22.2%)9/9 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventRituximab Plus AtaciceptRituximab Plus Placebo
Transient ischaemic attackNervous system disorders1/181/9
Ruptured cerebral aneurysmNervous system disorders0/181/9
DemyelinationNervous system disorders1/180/9
Nervous system disorderNervous system disorders1/180/9
Atrial fibrillationCardiac disorders1/180/9
Cardiac arrestCardiac disorders1/180/9
Ventricular fibrillationCardiac disorders1/180/9
ArthropathyMusculoskeletal and connective tissue disorders1/180/9
Muscular weaknessMusculoskeletal and connective tissue disorders1/180/9
Joint capsule ruptureInjury, poisoning and procedural complications1/180/9
Most frequent other events
Showing 10 of 99
Most frequent other events
EventRituximab Plus AtaciceptRituximab Plus Placebo
Injection site reactionGeneral disorders7/182/9
Upper respiratory tract infectionInfections and infestations3/183/9
Injection site erythemaGeneral disorders4/180/9
Injection site pruritusGeneral disorders4/180/9
HeadacheNervous system disorders4/181/9
Back painMusculoskeletal and connective tissue disorders3/181/9
PruritusSkin and subcutaneous tissue disorders3/180/9
InfluenzaInfections and infestations2/181/9
RhinitisInfections and infestations2/180/9
Urinary tract infectionInfections and infestations1/181/9

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)Rituximab Plus AtaciceptRituximab Plus PlaceboTotal
Mean57.0 ± 11.057.7 ± 11.557.2 ± 11.0
Gender
Gender(Participants)Rituximab Plus AtaciceptRituximab Plus PlaceboTotal
Female12820
Male617
08

Study locations

8 sites
  • Research Site
    Nice, France
  • Research Site
    Paris, France
  • Research Site
    Strasbourg, France
  • Research Site
    Amsterdam, Netherlands
  • Research Site
    Malmö, Sweden
  • Research Site
    Stockholm, Sweden
  • Research Site
    Newcastle, United Kingdom
  • Research Site
    Norwich, United Kingdom
09

References and documents

Publications

  • van Vollenhoven RF, Wax S, Li Y, Tak PP. Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial. Arthritis Rheumatol. 2015 Nov;67(11):2828-36. doi: 10.1002/art.39262. PubMed 26137975 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 6 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2008
First posted
Apr 23, 2008
Start
Mar 2008
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results first posted
Dec 30, 2016
Last update
Dec 30, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00664521
Responsible party
Sponsor
First posted
Apr 23, 2008
Start date
Mar 2008
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
Dec 30, 2016
Last update
Dec 30, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein

Start the discussion